Early Improvement in the First 2 Weeks as a Predictor of Treatment Outcome in Patients With Major Depressive Disorder: A Meta-Analysis Including 6562 Patients
The DOI matches its Crossref record.
Abstract
OBJECTIVE: New evidence indicates that treatment response can be predicted with high sensitivity after 2 weeks of treatment. Here, we assess whether early improvement with antidepressant treatment predicts treatment outcome in patients with major depressive disorder (MDD). DATA SOURCES: Forty-one clinical trials comparing mirtazapine with active comparators or placebo in inpatients and outpatients (all-treated population, N = 6907; intent-to-treat population, N = 6562) with MDD (DSM-III-R or DSM-IV Criteria) were examined for early improvement (>or= 20% score reduction from baseline on the 17-item Hamilton Rating Scale for Depression [HAM-D-17] within 2 weeks of treatment) and its relationship to treatment outcome. STUDY SELECTION: Data were obtained from a systematic search of single- or double-blind clinical trials (clinical trials database, Organon, a part of Schering-Plough Corporation, Oss, The Netherlands). All included trials (a total of 41) employed antidepressant treatment for more than 4 weeks and a maximum of 8 weeks. The studies ranged from March 1982 to December 2003. Trials were excluded if there were no HAM-D-17 ratings available, no diagnosis of MDD, or if the study was not blinded. Trials were also excluded if HAM-D-17 assessments were not available at week 2, week 4, and at least once beyond week 4. DATA SYNTHESIS: Early improvement predicted stable response and stable remission with high sensitivity (>or= 81% and >or= 87%, respectively). Studies utilizing rapid titration vs. slow titration of mirtazapine demonstrated improved sensitivity for stable responders (98%, [95% CI = 93% to 100%] vs. 91% [95% CI = 89% to 93%]) and stable remitters (100%, [95% CI = 92% to 100%] vs. 93% [95% CI = 91% to 95%]). Negative predictive values for stable responders and stable remitters were much higher (range = 82%-100%) than positive predictive values (range = 19%-60%). CONCLUSIONS: These results indicate that early improvement with antidepressant medication can predict subsequent treatment outcome with high sensitivity in patients with major depressive disorder. The high negative predictive values indicate little chance of stable response or stable remission in the absence of improvement within 2 weeks. A lack of improvement during the first 2 weeks of therapy may indicate that changes in depression management should be considered earlier than conventionally thought.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“although 60% of persons who achieved remission in the STAR * D trial with level 1 treatment did so after week 6 of treatment”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [168]
In the citing paper
“The adequate duration of an antidepres sant trial is generally considered to be 4- 6 weeks at optimal dosing”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [168]
In the citing paper
“the partial responses at 2 weeks have, nonetheless, been shown to be strongly correlated with subsequent remission [19,51].”
Citations
Cited by
Items 301–341 of 341
Estévez, F. A., & Bisén, J. R. D. (2011) · Elsevier eBooks · doi:10.1016/b978-84-8086-875-4.50010-0
Les effets précoces des antidépresseurs
Llorca, P. (2012) · L Encéphale · doi:10.1016/s0013-7006(12)70076-3
Phillips, J. L. (2015) · uO Research (University of Ottawa) · doi:10.20381/ruor-2800
“At study visits (once every two weeks), patients were assessed by administration of the MADRS, if an approximate 20% symptom improvement was not detected (Szegedi et al., 2009), an increase in doses (if tolerated), a change in medication, or an augmentation strategy was implemented.”
BackgroundMethodGroße Wirkung in kleiner Gruppe?
Helmreich, I., & Tadić, A. (2012) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-012-0116-9
La réponse insuffisante : définition et implications
Haffen, É., & Poulet, E. (2016) · L Encéphale · doi:10.1016/s0013-7006(16)30017-3
“[19] Szegedi A, Jansen WT, van Willigenburg AP et al.”
BackgroundInfluentialPrediction of Treatment Response in Depression Based on Genetic Factors from the Practical Viewpoint
Kato, M. (2013) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.44.117
Conflicting perspectives on neurobehavioral theories of the depressive disorders and drug actions
Katz, M. M. (2016) · Acta Neuropsychiatrica · doi:10.1017/neu.2016.35
Antidépresseurs : aspects thérapeutiques
Souaiby, L., Gauthier, C., Poirier, M., Olié, J., Gaillard, R., & Krebs, M. (2016) · Time to knit · doi:10.1016/s0246-1072(16)75752-x
Leucht, S. (2013) · Springer eBooks · doi:10.1007/978-3-642-27772-6_244-2
Auch bei ehemaligen Non-Respondern ein Prädiktor für den Therapieerfolg
Diener, A. T. (2013) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-013-0049-y
Genital and sphincter symptoms in multiple sclerosis; frequency, course and response to pancorphen.
WILDER, J. (1954) · PubMed
Wang, H., Wang, L., & Xiao, J. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001231
Laux, G. (2016) · Springer eBooks · doi:10.1007/978-3-642-45028-0_67-1 · Cited by 1
Laux, G. (2011) · Springer eBooks · doi:10.1007/978-3-642-03637-8_55
Pharmacological Treatment of Acute Bipolar Depression
Sachs, G. S. (2016) · Milestones in drug therapy · doi:10.1007/978-3-319-31689-5_9
Leucht, S. (2015) · Springer eBooks · doi:10.1007/978-3-642-36172-2_244
Antidepressants: Indications, Contraindications, Interactions, and Side Effects
Corponi, F., Fabbri, C., & Serretti, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_29
Modern approaches to treatment of depressive disorders in cardiological patients
Filippova, N. V., Barylnik, Y. B., Богданова, Т. М., Shchelchkova, A. A., & Mozgacheva, E. S. (2023) · Vestnik nevrologii psihiatrii i nejrohirurgii (Bulletin of Neurology Psychiatry and Neurosurgery) · doi:10.33920/med-01-2304-05
Bandu, R., Lee, H. J., Lee, H. M., Ha, T. H., Lee, H., Kim, S. J., Ha, K., & Kim, K. P. (2023) · Mass Spectrometry · doi:10.5702/massspectrometry.a0123
Maier, H. B., Borchert, A., Neyazi, A., Moschny, N., Schülke, R., Bundies, G. L., Folsche, T., Gaspert, A., Seifert, J., Bleich, S., et al. (2024) · Pharmacopsychiatry · doi:10.1055/a-2292-1438
“Response rates decline even lower to about 10 % when there is no response within the first three weeks [8].”
BackgroundManagement of Major Depressive Disorder: Basic Principles
Arnone, D., Tirumalaraju, V., & Selvaraj, S. (2024) · Cambridge University Press eBooks · doi:10.1017/9781108973922.019
Les troubles psychiatriques résistants
Holtzmann, J. (2015) · Presses universitaires de Grenoble eBooks · doi:10.3917/pug.bouv.2015.01.0135
Antidépresseurs : aspects thérapeutiques
Chalah, M. A., & Gaillard, R. (2025) · Encyclopédie médico-chirurgicale. Psychiatrie · doi:10.1016/s0246-1072(25)46992-2
Cheng, C., Kao, W.-Y., Lin, M., Su, M., Wu, C., Fan, C. C., & Wang, S. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02242-9 · Cited by 1
“A meta-analysis of clinical trials suggested that nonresponse can be reliably predicted within 2 weeks after initiating an antidepressant treatment [18].”
Nguyen, Q. K. D., Solanki, P., Thomas, E. H. X., Cerins, A., Hahn, L. A., Galletly, C. A., Fitzgerald, P. B., & Chen, L. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120581
White Matter Stratification in Depression Predicts Multidimensional Antidepressant ResponsesPreprint
Qin, J., Wang, X., Ni, H., Wu, Y., Liu, H., Hua, L., Yan, R., Tang, H., Zhao, P., Yao, Z., et al. (2025) · medRxiv · doi:10.64898/2025.12.08.25341854
Developing a More Effective and More Efficient Clinical Trial Model
Katz, M. M. (2013) · SpringerBriefs in psychology · doi:10.1007/978-3-319-00389-4_8
Ma, H., Zhang, D., Wang, Y., Ding, Y., Yang, J., & Li, K. (2023) · Figshare · doi:10.6084/m9.figshare.23583571
Davoodi, A., VLACHOS, I. K., Bares, M., Brunovský, M., & Paluš, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.26.701781
Yang, M., Wang, L., Song, M. L., Yang, J., Wang, X., Zheng, Y., Hou, Z., Wang, R., & An, C. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-07921-5
“Emerging evidence indicates that early symptom improvement (within two weeks) strongly predicts long-term clinical outcomes [13], underscoring the imperative of identifying predictors of treatment response.”
Predictors of the Effectiveness of Psychedelics in Treating Depression—A Scoping Review
Chmiel, J., & Rybakowski, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052202 · Cited by 2
“These predictors can include clinical factors (e.g., symptom profiles, comorbidities), genetic markers, or even early treatment signals [42–44].”
White Matter Stratification in Depression Predicts Multidimensional Antidepressant ResponsesPreprint
Qin, J., Wang, X., Ni, H., Wu, Y., Liu, H., Hua, L., Yan, R., Tang, H., Zhao, P., Yao, Z., et al. (2026) · eLife · doi:10.7554/elife.110078
White Matter Stratification in Depression Predicts Multidimensional Antidepressant ResponsesPreprint
Qin, J., Wang, X., Ni, H., Wu, Y., Liu, H., Hua, L., Yan, R., Tang, H., Zhao, P., Yao, Z., et al. (2026) · eLife · doi:10.7554/elife.110078.1
Chang, Y., Hsieh, M., Ju, P., & Chang, C. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121696
Top 50 Cited Articles on the Treatment of Major Depressive Disorder
Albesher, A. A., Muflehi, N. A., Hakami, Y. A., Barnawi, J. A., Softah, R. E., Ghalib, L. H. A., Bukhari, M., Almotiri, R. A. M., Algethami, M. S., Mahboob, S. W., et al. (2026) · Cureus · doi:10.7759/cureus.107337
Shamabadi, A., Karami, R., Sadati, S., Farahmand, K., Ershadmanesh, M., Moosavi, R., Rahiminejad, F., Ardakani, M. R. K., & Akhondzadeh, S. (2026) · Depression and Anxiety · doi:10.1155/da/5812795
“Comparing early improvement (de fi ned as ≥ 20 % reduction in HDRS scores after 2 weeks [24]), response rates (de fi ned as ≥ 50 % reduction in HDRS scores) [25] at follow-up sessions, the time needed to respond, remission rates (a total score of ≤ 7 in the HDRS [25]) at follow-up sessions, HDRS…”
Yuxuan, H., Gao, J., Liu, Y., Zhong, R., Wu, Z., & Qiao, J. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-08336-y
“Conversely, MDD patients who showed no response after 2 weeks of treat-ment achieved a final remission rate of only 4% when the treatment regimen remained unchanged [7].”
d’Andrea, G., Cavallotto, C., Allegretti, R., Lupi, M., Carmassi, C., Ventriglio, A., Quattrone, D., Zanardi, R., Barlati, S., Martiadis, V., et al. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117419
The Randomization Effect in a Double-Blind Placebo-Controlled Depression Study
Targum, S. D., Ceesay, P., Lines, C., Thase, M. E., Sanacora, G., & Merola, A. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002250
Self-citationZhu, J., Zhao, C.-L., Yuan, Z., Huang, Y., Ji, W.-J., Fu, J., Xie, W., & Hu, J. (2026) · Research Square · doi:10.21203/rs.3.rs-10821681/v1
Kato, M., Baba, T., Sonoyama, T., & Iwata, N. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1891881
Metadata
- Authors
- Szegedi, A., Jansen, W. T., van Willigenburg, A. P. P., van der Meulen, E., Stassen, H. H., & Thase, M. E.
- Affiliations
- University of Pennsylvania (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2009-02-24
- Volume
- 70
- Issue
- 3
- Pages
- 344-353
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2132699864
- Cited by
- 341
- References
- 0
- Citations by year
- 2026: 22 · 2025: 11 · 2024: 17 · 2023: 25 · 2022: 23 · 2021: 18 · 2020: 13 · 2019: 23 · 2018: 14 · 2017: 20 · 2016: 20 · 2015: 23 · 2014: 14 · 2013: 25 · 2012: 24
- FWCI
- 17.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- major depressive disorder, mirtazapine, early treatment response, treatment outcome prediction, antidepressant response, remission, rapid titration, dose titration, Hamilton Depression Rating Scale, predictive validity, negative predictive value, positive predictive value, sensitivity and specificity, antidepressant trials, inpatients and outpatients, treatment-resistant depression
- MeSH terms
- Mirtazapine, Antidepressive Agents, Clinical Trials as Topic, Major Depressive Disorder, Humans, Mianserin, Personality Inventory, Prognosis, Time Factors, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.